The Medical Letter on Drugs and Therapeutics
IV Meloxicam (Anjeso) for Pain
June 29, 2020 (Issue: 1601)The FDA has approved Anjeso (Baudax Bio), an IV formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for once-daily treatment of moderate to severe pain in adults. Oral meloxicam (Mobic, and others), which is only...more
- Nonopioid drugs for pain. Med Lett Drugs Ther 2018; 60:24.
- N Singla et al. Efficacy and safety of intravenous meloxicam in subjects with moderate-to-severe pain following abdominoplasty. Plast Reconstr Surg Glob Open 2018; 6:e1846.
- RA Pollak et al. Efficacy and safety of intravenous meloxicam in patients with moderate-to-severe pain following bunionectomy: a randomized, double-blind, placebo-controlled trial. Clin J Pain 2018; 34:918.
- SD Bergese et al. A phase 3, randomized, placebo-controlled evaluation of the safety of intravenous meloxicam following major surgery. Clin Pharmacol Drug Dev 2019; 8:1062.
- ER Viscusi et al. Intravenous meloxicam for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects. Reg Anesth Pain Med 2019 February 7 (epub).
- DK Li et al. Use of nonsteroidal antiinflammatory drugs during pregnancy and the risk of miscarriage. Am J Obstet Gynecol 2018; 219:275.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019 November 6 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.